Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Document › Details

Cellectricon AB. (1/26/17). "Press Release: Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program Utilizing High-quality Human iPSC-based Discovery Services for CNS and Pain Research". Mölndal & Cambridge.

Organisations Organisation Cellectricon AB
  Group Cellectricon (Group)
  Organisation 2 Censo Biotechnologies Ltd.
  Group Axol Bioscience (Group)
Products Product drug screening (technology)
  Product 2 iPSC technology (induced pluripotent stem cell technology)
Index term Index term Cellectricon–Censo Biotechnologies: drug discovery services, 201701– collab offer joint tech access program for human iPSC-based discovery services
Persons Person Karila, Paul (Cellectricon 201206– Head of Discovery Services before AstraZeneca)
  Person 2 Courtney, Aidan (Roslin Cells 201111 CEO)

Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.

The approach combines induced pluripotent stem cell-derived (iPSC-derived) cells, sourced and produced by Censo, with Cellectricon’s unique screening technologies, IP and expertise. The platform will enable high quality phenotypic screening of medium throughput libraries in customized human iPSC-derived diseased and healthy control models. Hits can be further evaluated in secondary/safety assays using human iPSC-derived cardiomyocytes and CNS neurons. This battery of human, functional assays will produce a highly refined short list of compounds ready for clinical testing.

“Differences in target composition and neuronal processing between humans and model organisms may lead to poor translation between animal studies and the clinical setting. By gaining access to human cells from virtually any disorder, our collaboration with Censo has significantly enhanced our discovery services offering for CNS and chronic pain research. We can now detect compound effects both on the cellular and network level,” said Cellectricon’s VP Discovery Services Paul Karila. “Offering better clinical translation through the application of a fully humanized screening platform, this novel program will accelerate our clients’ discovery efforts in CNS and pain research.”

Censo’s CEO Aidan Courtney added, “There is an excellent alignment between Censo and Cellectricon. Our extensive expertise in the production of ethically approved human iPSCs and derivatives adds further value to Cellectricon’s proprietary discovery services. We are very excited that this program will enable clients to access highly relevant screening cascades.”

For more information on Cellectricon’s Pain and CNS Discovery Services, please visit

For more information on Censo Biotechnologies’ stem cell expertise and capabilities please visit

Services Enquiries

Cellectricon AB
Jennie Svensson Dalén – Manager, Global customer support
T: +46 (0)733 67 35 31 E:

Censo Biotechnologies Ltd
Ashley Barnes – Head of Drug Discovery Services
T: +44 (0)1223 804 095 E:

Record changed: 2023-06-05


Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Twist Bioscience Variant Libraries Built Your Way 650x300px

» top